Table 6.

Performance of the Novodiag® Covid-19 assay and the Xpress® SARS-CoV-2 assay in the preliminary evaluation.

		Agreement compared to combination reference
		Novodiag® Covid-19, n=106		Xpress® SARS-CoV-2, n=90
		No/reference	Agreement % (95% CI)	No/reference	Agreement % (95% CI)
Posit	Total	57/61	93.4 (84.3-97.4)	60/60	100 (94.0-100)
	Ct < 20	15/15	100 (79.6-100)	15/15	100 (79.6-100)
	Ct 20-30	38/39	97.4 (86.8-99.5)	38/38	100 (90.8-100)
	Ct > 30	4/7	57.1 (25.0-84.2)	7/7	100 (64.6-100)
Negat	No Ct	45/45	100 (92.1-100)	30/30	100 (88.6-100)